SeekingAlpha reported that Insulet CEO Shacey Petrovic, speaking at the Nasdaq Investor Conference, said the regulatory agency will likely not complete its review of the next-generation Omnipod 5 before the end of the year, meaning the launch projected for the fourth quarter of 2021 is now expected for the first quarter of 2022.
Get the full story at our sister site, Drug Delivery Business News.